OR WAIT 15 SECS
February 21, 2017
AcelRx Pharmaceuticals (Redwood City, CA), a specialty pharmaceutical company focused on innovative therapies for the treatment of moderate-to-severe acute pain, announced that Vincent J. Angotti has been appointed chief executive officer and a member of the company's board of directors, effective Monday, March 6, 2017. Mr. Angotti succeeds Howie Rosen, who will continue on the AcelRx board of directors, where he has served since 2008. Angotti previously served as SVP and chief commercialization officer at XenoPort from 2008 to 2012, promoted to EVP and COO in 2012 and to CEO in 2015. During his tenure at XenoPort, he was involved in the re-acquisition of Horizant from GSK and implemented a successful re-branding and re-launch strategy leading to XenoPort's acquisition by Arbor Pharmaceuticals, LLC in 2016. Previous to joining XenoPort, Mr. Angotti held senior sales and marketing positions at Reliant Pharmaceuticals, Inc. from 2001 2008.